Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 2, 2010, Pages 121-124

  Lam, Anthony P ^a   Sparano, Joseph A ^a   Vinciguerra, Vincent ^b   Ocean, Allyson J ^c   Christos, Paul ^c   Hochster, Howard ^d   Camacho, Fernando ^a   Goel, Sanjay ^a   Mani, Sridhar ^a   Kaubisch, Andreas ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LEUKOPENIA; LOCAL METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRYOSTATINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PANCREATIC NEOPLASMS; PROTEIN KINASE C; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951078231     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181a31920     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008;112:243-249.
3. Russo S, Butler J, Ove R, et al. Locally advanced pancreatic cancer: a review. Semin Oncol. 2007;34:327-334.
4. Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer. 2007;96:1183-1190.
5. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
6. Senderowicz AM, Johnson JR, Sridhara R, et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park). 2007;21:1696 -1706; discussion 1706- 1709, 1712, 1715.
7. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs. 2006;15:1395-1410
8. Fishman DD, Segal S, Livneh E. The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int J Oncol. 1998;12:181-186.
9. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21:924-936.
10. Jarvis WD, Grant S. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999;17:227-240.
11. Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res. 2000;6:1498-1507.
12. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001;37:1-3.
13. Lopes G, Rocha Lima CM. Docetaxel in the management of advanced pancreatic cancer. Semin Oncol. 2005;32:S10-S23.
14. Lenzi R, Yalcin S, Evans DB, et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 2002;20:464-472.
15. Oettle H, Arnold D, Esser M, et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs. 2000;11: 635-638.
16. Whitehead RP, Jacobson J, Brown TD, et al; A Southwest Oncology Group study. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma. J Clin Oncol. 1997;15:2414-2419.
17. Ku GY, Ilson DH, Schwartz LH, et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008;62:875-880.
18. Ajani JA, Jiang Y, Faust J, et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006;24(4):353-357.
19. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer. 2007;7:554-562.